@viki.esp's tirzepatide regrets, fact-checked

Victoria Espinoza (@viki.esp) shared her top three regrets about starting tirzepatide, claiming she wished she'd done certain things differently. While she doesn't specify exactly what these regrets are in the caption, TikTok creators often discuss dosing schedules, side effect management, and lifestyle changes with GLP-1 medications.

What does this video actually claim?

Without seeing the full video content, Espinoza implies there are three specific strategies she wishes she'd known before starting tirzepatide for weight loss. The caption suggests these are actionable tips that could help others avoid her mistakes.

This type of content is common among GLP-1 influencers who share personal experiences. The problem is that individual experiences with tirzepatide vary significantly based on factors like starting weight, medical history, and adherence to lifestyle changes.

Most creators in this space discuss similar themes: starting doses, managing nausea, timing meals, or setting realistic expectations. But personal regrets aren't necessarily evidence-based recommendations.

Does the science support common tirzepatide advice?

The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) provides the clearest picture of what actually works with tirzepatide. Participants lost 20.9% of body weight on average with the 15mg dose over 72 weeks.

The study protocol included specific guidance that creators often echo: starting at 2.5mg weekly, escalating every four weeks, and maintaining consistent injection timing. These aren't just suggestions but the actual dosing schedule that produced those results.

Where creators often go wrong is extrapolating from their personal experience. The trial showed significant individual variation in weight loss, ranging from 5% to over 30% among participants. What worked for Espinoza might not work for her followers.

Side effect management strategies also vary. In SURMOUNT-1, 81% experienced gastrointestinal side effects, but severity and duration differed widely between participants.

What do most people actually regret about starting tirzepatide?

Real-world data suggests the most common regrets involve unrealistic expectations about speed and magnitude of weight loss. The clinical trials showed gradual, sustained weight loss over 72 weeks, not rapid dramatic changes.

Many patients also regret not addressing insurance coverage earlier. Tirzepatide costs around $1,000 monthly without insurance, and prior authorization can take weeks to process.

Another frequent regret is underestimating the lifestyle changes required. The SURMOUNT-1 trial included reduced-calorie diet counseling and increased physical activity. The medication isn't effective without these components.

Some patients regret not discussing realistic timelines with their healthcare provider. Weight loss typically begins in weeks 4-8 and continues throughout the first year of treatment.

What should you actually know about starting tirzepatide?

The FDA approved tirzepatide (Zepbound) for chronic weight management in adults with BMI ≥30 or ≥27 with weight-related conditions. It's not a cosmetic weight loss option for people within normal BMI ranges.

Starting dose is always 2.5mg weekly for four weeks, then escalated based on tolerance and efficacy. You can't shortcut this titration schedule without risking severe gastrointestinal side effects.

Expected weight loss is 15-20% of body weight over 68-72 weeks, based on clinical trial data. Individual results vary, but this provides realistic expectations rather than social media success stories.

The medication requires ongoing lifestyle changes and medical monitoring. It's not a quick fix but a long-term treatment approach for chronic weight management.